MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1

Area of Science:

• Molecular Biology
• Epigenetics
• Oncology

Background:

• MicroRNAs (miRNAs) are key epigenetic regulators of gene expression.
• Osteosarcoma cancer stem cells (CSCs) drive tumor progression, but their miRNA regulation is unclear.
• Understanding miRNA roles in osteosarcoma CSCs is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of miR-26a in regulating osteosarcoma cancer stem cells.
• To identify the molecular targets and signaling pathways affected by miR-26a.
• To evaluate the clinical relevance of miR-26a expression in osteosarcoma patients.

Main Methods:

• Osteosarcoma CSCs were isolated using sarcosphere generation, chemodrug, and ALDH activity selection.
• Lentiviral vectors were used to overexpress miR-26a in osteosarcoma cell lines (ZOS, 143B).
• In vitro and in vivo tumor growth assays, stem cell marker analysis, and in situ hybridization in patient tumors were performed.

Main Results:

• miR-26a was significantly downregulated in osteosarcoma CSCs.
• miR-26a overexpression reduced stem cell markers, sarcosphere formation, and ALDH activity.
• miR-26a directly targets Jagged1, inhibiting the Jagged1/Notch signaling pathway.
• Reduced miR-26a expression in patient tumors correlated with lung metastasis and poor survival.

Conclusions:

• The miR-26a/Jagged1/Notch pathway is essential for maintaining stem-like properties in osteosarcoma cells.
• miR-26a acts as a tumor suppressor by targeting Jagged1 and inhibiting Notch signaling.
• miR-26a represents a potential therapeutic target for osteosarcoma treatment, particularly in patients with metastasis.